文献速递糖尿病

瑞典2型糖尿病人群中GLP-1受体激动剂与SGLT2抑制剂治疗中断情况

Treatment discontinuation among users of GLP-1 receptor agonists and SGLT2 inhibitors in a national population of individuals with type 2 diabetes.
PubMed 文献 · Diabetologia · 2025-05-02

基于瑞典全国登记数据,纳入2017–2021年首次处方GLP-1受体激动剂或SGLT2抑制剂的2型糖尿病患者,评估治疗中断、重启及同类药物间换药情况。GLP-1受体激动剂与SGLT2抑制剂1年中断累积发生率分别为23.6%与27.9%,3年分别为38.5%与45.9%;中断后重启比例较高,持续治疗者约70%–80%。

要点

  • GLP-1受体激动剂3年治疗中断累积发生率为38.5%,SGLT2抑制剂为45.9%。
  • 中断后1年重启累积发生率GLP-1受体激动剂为41.1%,SGLT2抑制剂为40.4%。
  • 同类药物间换药比例GLP-1受体激动剂为22.9%,SGLT2抑制剂为2.1%。

核心结论

  • 约半数起始GLP-1受体激动剂或SGLT2抑制剂的2型糖尿病患者在5年随访内中断治疗。
  • 中断治疗者中超过半数随后重启治疗,持续治疗比例在两药起始后1–5年间约为70%–80%。
  • 作者认为长期使用药物的患者比例高于仅关注治疗中断的分析所显示的比例。
  • 与治疗中断相关的患者特征在GLP-1受体激动剂与SGLT2抑制剂间相似。

研究设计与样本

  • 基于瑞典全国登记数据的队列分析,分别纳入2017–2021年间首次处方GLP-1受体激动剂或SGLT2抑制剂的2型糖尿病患者。
  • GLP-1受体激动剂新使用者73,895例,SGLT2抑制剂新使用者113,207例。
  • 采用Aalen-Johansen估计量计算中断与重启的累积发生率,采用Fine-Gray子分布风险模型评估临床变量与中断风险的关联。
  • 治疗状态以最近一次处方预估结束日期前续药为准,并设90天宽限期。

主要发现

  • GLP-1受体激动剂使用者治疗中断累积发生率1年为23.6%,3年为38.5%。
  • SGLT2抑制剂使用者治疗中断累积发生率1年为27.9%,3年为45.9%。
  • 中断后重启累积发生率GLP-1受体激动剂1年为41.1%、3年为57.4%,SGLT2抑制剂1年为40.4%、3年为55.7%。
  • 宽限期在60天至365天间变动时,3年中断率GLP-1受体激动剂为23.3%–43.6%,SGLT2抑制剂为28.8%–50.6%。
  • 无论既往中断情况,两药在起始后1–5年间持续治疗比例约为70%–80%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Our aim was to assess treatment discontinuation, reinitiation and switching between drugs within the same drug class for glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter 2 (SGLT2) inhibitors in individuals with type 2 diabetes. METHODS: We used data from nationwide registers in Sweden to perform separate analyses for all patients with type 2 diabetes who filled a first prescription of a GLP-1 receptor agonist or an SGLT2 inhibitor between 2017 and 2021. Patients were considered to be on treatment for the period during which prescriptions were refilled before the estimated end date of the most recent prescription, including a 90-day grace period, i.e. the time allowed between and after prescriptions before treatment is considered as discontinued. We used the Aalen-Johansen estimator to estimate cumulative incidences of discontinuation and reinitiation, and Fine-Gray sub-distribution hazard models to assess the association of clinical variables with the risk of discontinuation. RESULTS: Among 73,895 new users of GLP-1 receptor agonists, the cumulative incidence of treatment discontinuation was 23.6% at 1 year and 38.5% at 3 years. Among patients who discontinued, the cumulative incidence of treatment reinitiation was 41.1% at 1 year and 57.4% at 3 years after discontinuation. Among 113,207 new users of SGLT2 inhibitors, the cumulative incidence of treatment discontinuation was 27.9% at 1 year and 45.9% at 3 years, with a cumulative incidence of reinitiation of 40.4% at 1 year and 55.7% at 3 years after discontinuation. When varying the grace period between 60 days and 365 days, treatment discontinuation rates at 3 years ranged from 23.3% to 43.6% among GLP-1 receptor agonist users and from 28.8% to 50.6% among SGLT2 inhibitor users. The proportion of patients who had ongoing treatment, regardless of previous discontinuation episodes, ranged between approximately 70% and 80% for both drugs during a 1-5 year period after treatment initiation across analyses using various grace periods. In terms of switching, 22.9% of the GLP-1 receptor agonist users and 2.1% of the SGLT2 inhibitor users switched between drugs within the same drug class. Patient characteristics associated with treatment discontinuation were similar for GLP-1 receptor agonists and SGLT2 inhibitors, although the association between higher BMI and a lower likelihood of treatment discontinuation was stronger for GLP-1 receptor agonists. CONCLUSIONS/INTERPRETATION: Approximately half of type 2 diabetes patients who had started using GLP-1 receptor agonists or SGLT2 inhibitors had discontinued treatment within 5 years of follow-up. However, more than half of those who discontinued treatment subsequently reinitiated treatment, such that the proportion with ongoing treatment was approximately 70-80% for both drugs during a 1-5 year period after treatment initiation. This suggests that the proportion of patients with long-term use of the medications is larger than indicated by analyses focusing on treatment discontinuation. Patient characteristics associated with treatment discontinuation were similar for GLP-1 receptor agonists and SGLT2 inhibitors.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Lim CE, Pasternak B, Eliasson B, et al. Treatment discontinuation among users of GLP-1 receptor agonists and SGLT2 inhibitors in a national population of individuals with type 2 diabetes. Diabetologia. 2025. PMID: 40316732. doi:10.1007/s00125-025-06439-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。